Mingowood Pharmacal

Mingowood PharmacalMingowood PharmacalMingowood Pharmacal
  • Home
  • Mission
  • Benefits
  • Better Medicine
  • Technology
    • Our Science
    • Demonstration
    • Stability Studies
    • ATR-FTIR
    • FAQ
    • Patents
  • About
    • Monetization Model
    • Announcements
    • Leadership
  • Contact
  • More
    • Home
    • Mission
    • Benefits
    • Better Medicine
    • Technology
      • Our Science
      • Demonstration
      • Stability Studies
      • ATR-FTIR
      • FAQ
      • Patents
    • About
      • Monetization Model
      • Announcements
      • Leadership
    • Contact

Mingowood Pharmacal

Mingowood PharmacalMingowood PharmacalMingowood Pharmacal
  • Home
  • Mission
  • Benefits
  • Better Medicine
  • Technology
    • Our Science
    • Demonstration
    • Stability Studies
    • ATR-FTIR
    • FAQ
    • Patents
  • About
    • Monetization Model
    • Announcements
    • Leadership
  • Contact

The Science behind our Technology

In the fast-evolving cannabinoids market, maintaining the potency of active agents is crucial. We are dedicated to preserving the therapeutic benefits of cannabinoid compounds, such as CBDA, THCA, CBGA, and CBCA.


Introducing @LDH™ Technology: Our patent-pending @LDH™ technology achieves over 90% encapsulation efficiency for acidic cannabinoids, ensuring maximum potency, stability, and long-term effectiveness.


Key Benefits Include:

  • Long-Term Stability and Protection: 
    • @LDH selectively encases acidic cannabinoids (CBDA, THCA, CBGA, CBCA) to prevent degradation, ensuring accurate dosing and sustained product effectiveness. 
    • Strongly inhibits the formation of degradants, including scheduled compounds like       Δ-9 tetrahydrocannabinol (THC).
  • THCA Stability and Non-Psychoactive Properties: 
    • THCA does not convert to Δ-9 in vivo; it metabolizes into 11-hydroxy molecules       without psychotropic effects.
  • Processable and Scalable Formulation: 
    • The combination of @LDH technology and acidic cannabinoids produces a fine       powder from inexpensive, considered safe (GRAS) excipients.
    • Validated scalability ensures efficient production.
  • Versatile Delivery and Administration: 
    • The finished product can be used in various delivery systems and administration routes, including dispersions, emulsions, injectables, sublingual, oral, and inhalation.
    • @LDH technology provides taste and smell masking, enhancing user experience.
  • Regulatory-Friendly Formulation: 
    • Avoids creating new chemical entities (NCEs), expedites market entry, and       efficiently navigates regulatory obstacles.
    • GRAS formulation.
    • @LDH technology allows production flexibility regarding equipment and starting materials. 
  • Temperature Resilience: 
    • Eliminates the need for complex cold storage by providing unparalleled protection       from elevated temperatures.
  • Prevention of Degradation: 
    • Prevents decarboxylation and oxidation.
  • Precise Dosing: 
    • Ensures accurate and consistent dosing.


Our formulation employs cost-effective GRAS ingredients and standard pharmaceutical processes, resulting in @LDH™ intercalated material. These intercalates ensure efficient delivery, can be tailored for various administration routes, and meet stringent regulatory standards.


Mingowood Pharmacal

Copyright © 2024 Mingowood Pharmacal - All Rights Reserved.

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept